失衡cAMP和Ras/MAPK通路作为皮肤神经纤维瘤的治疗策略
Helena Mazuelas1, Miriam Magallón-Lorenz1, Itziar Uriarte-Arrazola1
1Hereditary Cancer Group, Translational Cancer Research Program, and.
JCI insight
|January 4, 2024
概括
将MEK抑制剂与cAMP提升剂相结合,为皮肤神经纤维瘤 (cNFs) 提供了潜在的治疗方法. 这种方法永久地阻止了施万细胞的扩张,与单独使用MEK抑制剂不同,改善了NF1患者的生活质量.
科学领域:
- 在瘤学瘤学.
- 细胞生物学 细胞生物学
- 皮肤病学 皮肤病学
背景情况:
- 皮肤神经纤维瘤 (cNFs) 是一种良性施万细胞瘤,在神经纤维瘤类型1 (NF1) 中很常见.
- 由于瘤负担,NF1相关的cNF显著损害患者的生活质量.
- 瘤生长涉及NF1-/- 施万细胞增殖和微环境相互作用.
研究的目的:
- 研究人类cNF衍生的施万细胞 (SCs) 和纤维细胞 (FBs) 之间的分子交叉.
- 确定针对cNFs的SC增殖和生存的治疗策略.
- 探索像cAMP这样的信号通路在cNF发育中的作用.
主要方法:
- 在SC-FB共同培养中分析基因表达特征.
- 参与免疫细胞迁移的分泌蛋白质的验证.
- 在体外和3D神经纤维球模型测试药物疗效.
- 使用G蛋白结合受体68 (GPR68) 激活剂和MEK抑制剂 (MEKi) 的组合疗法.
主要成果:
- 确定了一个独特的SC-FB相互作用签名,包括GPR68和cAMP通路组件.
- 奥格林 (GPR68激活剂) 和塞卢梅替尼 (MEKi) 的组合降低了SC活力,并诱导了分化/死亡.
- 这种组合疗法导致SC增殖的永久停止,与单独使用塞卢美替尼布不同.
- 与其他GPR68激活剂或cAMP增强剂结合塞卢美替尼布观察到类似的效果.
结论:
- SC-FB 交叉对应在cNF 病原和免疫细胞招募中起作用.
- 同时针对Ras (通过MEKi) 和cAMP途径,为cNF提供了一个有前途的治疗策略.
- 结合MEKi和cAMP提升器,可长期抑制SC扩张,从而可能导致有效的cNF治疗.
相关概念视频
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


